CNX’s $400M Move: Strategic Shift or Risky?by Mark Eisenberg 12.02.2024CNX Resources raises $400 million in senior notes offering and launches tender offer, positioning the company for future growth in ...
Saudi Market Hits Record High: Pharma Leads, Oil Slipsby Terry Bingman 12.02.2024The Saudi Arabia stock market hits a new 52-week high as pharmaceutical and telecom stocks surge, attracting investor attention.
Tod’s Stock Surges 17% Amid Delisting and Takeover Rumorsby Terry Bingman 12.02.2024Shares of Tod's SpA surged 17% after a delisting plan and takeover bid by L Catterton, valuing the luxury goods ...
Novo Nordisk’s Sales Surge: Eyeing $7B Annual Investmentby Mark Eisenberg 12.02.2024Novo Nordisk sees massive sales jump and expects further growth in 2024, driven by the demand for its diabetes and ...
Shell’s Bonny Terminal Fuels Nigeria’s Refinery Revival.by Mark Eisenberg 12.02.2024Shell Nigeria has resumed oil supply to the Port Harcourt Refinery after a five-year outage, reducing the country's dependence on ...
SU Group Holdings Wins Major Hong Kong Security Projectby Lilu Anderson 12.02.2024SU Group Holdings Limited announces a prestigious security system contract in Hong Kong, showcasing their expertise and potential for growth.
Martin Marietta’s Bold Acquisition Boosts SE Footprintby Mark Eisenberg 12.02.2024Martin Marietta Materials is set to acquire 20 aggregates operations from Blue Water Industries for $2.05 billion, expanding its footprint ...
Gold and Silver Slide as Oil Prices Surgeby Lilu Anderson 12.02.2024Today's commodity market update highlights fluctuations across sectors, including declines in precious and industrial metals, mixed performance in energy commodities, ...
French Electric Car Subsidy Program Pause: Demand Surgeby Lilu Anderson 12.02.2024The French government has halted its electric car subsidy program due to overwhelming demand. The initiative aimed to make electric ...
AN2 Therapeutics Pauses Trial: Efficacy Concerns Riseby Mark Eisenberg 12.02.2024AN2 Therapeutics voluntarily pauses enrollment in its epetraborole clinical trial due to lower efficacy. Safety is not a concern. The ...